Literature DB >> 2913082

Treatment of neoplastic skin lesions with intralesional interferon.

L Wickramasinghe1, T C Hindson, H Wacks.   

Abstract

Nineteen patients with skin neoplasms were treated with intralesional recombinant interferon-alpha 2. There were 11 basal cell carcinomas, 3 squamous cell carcinomas, 4 solar keratoses, and 1 keratoacanthoma. Biopsy specimens were taken before and 2 months after treatment in most cases. Lesions were injected three times weekly for 3 weeks (nine total injections) with 0.9 X 10(6) IU (0.3 ml) of interferon-alpha 2 (total dose 8.1 X 10(6) IU). Clinical and histologic examination revealed three squamous cell carcinomas that had cleared. No basal cell carcinomas had resolved but the keratoses were clinically clear and histologically less active. One keratoacanthoma resolved.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2913082     DOI: 10.1016/s0190-9622(89)70009-8

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

1.  Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon.

Authors:  N Mozzanica; A Cattaneo; V Boneschi; L Brambilla; E Melotti; A F Finzi
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

2.  Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide.

Authors:  S A Buechner; M Wernli; T Harr; S Hahn; P Itin; P Erb
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

3.  Treatment of Basal Cell Carcinoma Located in the Head and Neck Region with Intralesional Interferon alpha-2a : Evaluation of Long-Term Follow-Up Results.

Authors:  Seher Bostanci; Pelin Kocyigit; Ayşegül Alp; Cengizhan Erdem; Erbak Gürgey
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.